Nuclomedone - Beijing Tide Pharmaceutical

Drug Profile

Nuclomedone - Beijing Tide Pharmaceutical

Alternative Names: DRP-043; NSL 043; SD-118; TEI 3096; TI 31

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Teijin
  • Developer Beijing Tide Pharmaceutical; Teijin
  • Class Antirheumatics; Small molecules; Thiazoles
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Neuropathic pain
  • Discontinued Rheumatic disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Neuropathic-pain in China (PO, Capsule)
  • 13 Aug 2012 Beijing Tide Pharma acquires nuclomedone assets from Sosei Co. Ltd
  • 06 Sep 2011 No development reported - Phase-I for Neuropathic pain in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top